NATCO Pharma posted robust financials: revenue grew 16% to ₹4,784 Cr, PAT jumped 36% to ₹1,883 Cr, with 53.30% EBITDA.

The company expanded global presence and R&D (₹373.3 Cr spend) in new therapies.

NATCO earned a GreenCo Gold rating, upholding strong compliance with no product recalls.